Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
762.00
+5.19 (0.69%)
Nov 18, 2024, 4:00 PM EST - Market closed
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 13,450 employees as of December 31, 2023. The number of employees increased by 1,599 or 13.49% compared to the previous year.
Employees
13,450
Change (1Y)
1,599
Growth (1Y)
13.49%
Revenue / Employee
$1,029,524
Profits / Employee
$346,059
Market Cap
81.98B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | 8,100 | 700 | 9.46% |
Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
Dec 31, 2017 | 6,200 | 800 | 14.81% |
Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
Dec 31, 2014 | 2,925 | 585 | 25.00% |
Dec 31, 2013 | 2,340 | 390 | 20.00% |
Dec 31, 2012 | 1,950 | 246 | 14.44% |
Dec 31, 2011 | 1,704 | 309 | 22.15% |
Dec 31, 2010 | 1,395 | 366 | 35.57% |
Dec 31, 2009 | 1,029 | 110 | 11.97% |
Dec 31, 2008 | 919 | 237 | 34.75% |
Dec 31, 2007 | 682 | 109 | 19.02% |
Dec 31, 2006 | 573 | -15 | -2.55% |
Dec 31, 2005 | 588 | -142 | -19.45% |
Dec 31, 2004 | 730 | 86 | 13.35% |
Dec 31, 2003 | 644 | -25 | -3.74% |
Dec 31, 2002 | 669 | 94 | 16.35% |
Dec 31, 2001 | 575 | 84 | 17.11% |
Dec 31, 2000 | 491 | 54 | 12.36% |
Dec 31, 1999 | 437 | 66 | 17.79% |
Dec 31, 1998 | 371 | 101 | 37.41% |
Dec 31, 1997 | 270 | 27 | 11.11% |
Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
CVS Health | 300,000 |
Elevance Health | 104,900 |
Medtronic | 95,000 |
Becton, Dickinson and Company | 73,000 |
The Cigna Group | 72,500 |
GSK | 70,212 |
McKesson | 51,000 |
REGN News
- 3 days ago - Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewsWire
- 3 days ago - Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 5 days ago - Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - GlobeNewsWire
- 7 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 12 days ago - Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis - GlobeNewsWire
- 12 days ago - Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis - GlobeNewsWire
- 14 days ago - Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors - Business Wire
- 14 days ago - Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade) - Seeking Alpha